×

Indications

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal Read More

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia® reduces the incidence of vertebral, nonvertebral, and hip fractures.

Prolia® is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Prolia® is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. In these patients Prolia® also reduced the incidence of vertebral fractures.

Prolia® is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. Close

For the treatment of postmenopausal women with osteoporosis at high risk for fracture


With 1 dose every 6 months, Prolia® follows your PMO patients all year long.

  • 60 mg subcutaneous injection in the upper arm, upper thigh, or abdomen by a healthcare professional
  • Pre-existing hypocalcemia must be corrected prior to initiating therapy with Prolia®. Adequately supplement all patients with calcium and vitamin D
  • Multiple vertebral fractures have been reported following Prolia® discontinuation
RISK EVALUATION AND MITIGATION STRATEGY (REMS)

Learn about coverage and multiple fulfillment solutions available for your Prolia® patients.

Prolia® (denosumab) safety profile.4

Learn about adverse reactions reported in women with PMO from the pivotal phase 3 fracture trial.4

Adverse Reactions

Learn about the Prolia® Risk Evaluation and Mitigation Strategy Program.

REMS

Learn about Prolia® Important Safety Information.

Important Safety Information
Prolia® is
1 Shot Every
6
Months4

Single-use
prefilled 1 mL syringe

  • 60 mg subcutaneous injection in the upper arm, upper thigh, or abdomen by a healthcare professional
  • Pre-existing hypocalcemia must be corrected prior to initiating therapy with Prolia®. Adequately supplement all patients with calcium and vitamin D
  • Multiple vertebral fractures have been reported following Prolia® discontinuation
  • As a subcutaneous injection, Prolia® does not undergo first-pass metabolism6
  • May lessen patient pill burden
Dosing

Important Safety Information

Following discontinuation of Prolia® treatment, fracture risk increases, including the risk of multiple vertebral fractures. Evaluate an individual’s benefit/risk before initiating treatment with Prolia®. If Prolia® treatment is discontinued, consider transitioning to an alternative antiresorptive therapy.